<DOC>
	<DOCNO>NCT02348723</DOCNO>
	<brief_summary>The primary objective trial ass safety uninterrupted dabigatran etexilate periprocedural anticoagulant regimen compare uninterrupted warfarin regimen NVAF patient undergo AF ablation PROBE ( Prospective , randomize , open label , blind end point ) active control study . Secondary objective assess additional safety endpoint efficacy clinical setting . It intend assess confirmatory hypothesis , exploratory study .</brief_summary>
	<brief_title>Uninterrupted Dabigatran Etexilate Comparison Uninterrupted Warfarin Pulmonary Vein Ablation ( RE-CIRCUIT )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion : Male female patient age &gt; = 18 year . Patients eligible treatment dabigatran etexilate 150 mg b.i.d . accord local label . Treatment na√Øve patient patient oral anticoagulant treatment VKA , dabigatran etexilate , rivaroxaban , apixaban edoxaban . Patient paroxysmal persistent NVAF plan catheter ablation AF unless perform investigational ablation technique . AF must document least either ECG , Holter monitoring , loop recorder , telemetry , transtelephonic monitoring , pacemaker cardiac defibrillator read out within 24 month prior screen ( Visit 1 ) . The patient must able give informed consent accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline local legislation and/or regulation . Exclusion criterion : Patients permanent AF . Patients AF felt secondary obvious reversible cause , limited , acute myocardial infarction , pulmonary embolism , recent surgery , pericarditis thyrotoxicosis . Patients LA size &gt; = 60 mm Patients contraindication systemic anticoagulation heparin , warfarin dabigatran etexilate Patients know allergy warfarin tablet excipients dabigatran etexilate excipients Mechanical biological heart valve prosthesis Severe renal impairment ( estimate CrCl calculate CockcroftGault equation ) &lt; 30mL/min screen Stroke within 1 month prior screen visit Major surgery per investigator judgement within previous month prior screen . Patient receive organ transplant wait list organ transplant History intracranial haemorrhage , intraocular , spinal , retroperitoneal nontraumatic intraarticular bleed Gastrointestinal haemorrhage within one month prior screening , unless , opinion investigator , cause permanently eliminate ( e.g . surgery ) . Major bleed episode ( ISTH definition ) one month prior screen visit . Haemorrhagic disorder bleed diathesis ( e.g . von Willebrand disease , haemophilia A B hereditary bleeding disorder , history spontaneous intraarticular bleeding , history prolong bleed surgery/intervention ) Anaemia ( haemoglobin &lt; 10g/dL ) thrombocytopenia include heparininduced thrombocytopenia ( platelet count &lt; 100 x 10^9/L ) screen Recent malignancy radiation therapy ( &lt; =6 month prior screen ) unless , opinion Investigator , estimate life expectancy great 36 month Active liver disease indicate least one following : Prior persistent alanine aminotransferase Aspartate transaminase alkaline phosphatase &gt; 3x upper limit normal and/or Known active hepatitis C and/or Known active hepatitis B and/or Known active hepatitis A Need continue treatment systemic ketoconazole , itraconazole , posaconazole , cyclosporine , tacrolimus , dronedarone , rifampicin , phenytoin , carbamazepine , St. John 's Wort cytotoxic/myelosuppressive therapy . Premenopausal ( last menstruation &lt; =1 year prior screen ) : Are pregnant breastfeeding plan become pregnant study Are surgically sterile Are child bear potential practising two acceptable method birth control , plan continue practise acceptable method birth control throughout trial Patients participate another trial investigational drug device within past 30 day precede screen visit participate another trial ( patient participate observational study exclude ) Patients willing able comply protocol requirement consider unreliable Investigator concerning requirement followup study and/or compliance study drug administration , life expectancy less expected duration trial due concomitant disease and/or subject institutionalise due official court order and/or vulnerable subject dependent Sponsor Investigator site , patient condition opinion Investigator , would allow safe participation study ( e.g . drug addiction , alcohol abuse ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>